Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Association of Chromosome 9p21 with Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data.

Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J, Van der Harst P, Tardif JC, Sattar N, Lang CC, Paré G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Mar 21. doi: 10.1161/CIRCGEN.119.002471. [Epub ahead of print]

PMID:
30897348
2.

Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium.

Patel R, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots M, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Paré G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Mar 21. doi: 10.1161/CIRCGEN.119.002470. [Epub ahead of print]

PMID:
30896328
3.

Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.

Kwakman JJM, van Kruijsdijk RCM, Elias SG, Seymour MT, Meade AM, Visseren FLJ, Punt CJA, Koopman M.

Acta Oncol. 2019 Mar;58(3):326-333. doi: 10.1080/0284186X.2018.1564840. Epub 2019 Jan 18.

4.

Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium.

Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC).

BMJ. 2019 Jan 10;364:k5301. doi: 10.1136/bmj.k5301.

5.

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.

Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN.

Eur Heart J. 2019 Jan 9. doi: 10.1093/eurheartj/ehy839. [Epub ahead of print]

PMID:
30629157
6.

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.

Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ.

J Am Heart Assoc. 2018 Aug 21;7(16):e009217. doi: 10.1161/JAHA.118.009217.

7.

[Cholesterol-lowering drugs in the elderly. When to initiate, maintain or discontinue therapy?]

Kleipool EEF, Dorresteijn JAN, Visseren FLJ, Hollander M, Peters MJL, Muller M.

Ned Tijdschr Geneeskd. 2018 Oct 5;162. pii: D2658. Dutch.

PMID:
30358363
8.

The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation.

Jaspers NEM, Ridker PM, Dorresteijn JAN, Visseren FLJ.

Curr Opin Lipidol. 2018 Dec;29(6):436-444. doi: 10.1097/MOL.0000000000000554.

PMID:
30234556
9.

Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease.

Kofink D, Muller SA, Patel RS, Dorresteijn JAN, Berkelmans GFN, de Groot MCH, van Solinge WW, Haitjema S, Leiner T, Visseren FLJ, Hoefer IE, Asselbergs FW; SMART Study Group.

PLoS One. 2018 Sep 7;13(9):e0202682. doi: 10.1371/journal.pone.0202682. eCollection 2018.

10.

Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension.

Van Der Sande NGC, Blankestijn PJ, Visseren FLJ, Beeftink MM, Voskuil M, Westerink J, Bots ML, Spiering W.

J Hypertens. 2019 Feb;37(2):398-405. doi: 10.1097/HJH.0000000000001885.

PMID:
30074565
11.

Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.

Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, Visseren FLJ, Imholz BPM, Roeters van Lennep JE, Huijgen R, Kastelein JJP, Hovingh GK.

J Clin Lipidol. 2018 Jul - Aug;12(4):972-980.e1. doi: 10.1016/j.jacl.2018.04.002. Epub 2018 Apr 18.

PMID:
29934068
12.

Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.

van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W; SMART-study group.

J Hypertens. 2018 Sep;36(9):1865-1873. doi: 10.1097/HJH.0000000000001785.

PMID:
29878973
13.

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.

Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JAN.

BMJ Open. 2018 May 26;8(5):e021309. doi: 10.1136/bmjopen-2017-021309.

14.

The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort.

Kranenburg G, Baas AF, de Jong PA, Asselbergs FW, Visseren FLJ, Spiering W; SMART study-group.

Eur J Med Genet. 2019 Feb;62(2):90-92. doi: 10.1016/j.ejmg.2018.05.020. Epub 2018 May 22.

PMID:
29800625
15.

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.

Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ.

Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.

16.

Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.

Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, Ho K, Ito S, Marks A, Naimark D, Nash DM, Navaneethan SD, Sarnak M, Stengel B, Visseren FLJ, Wang AY, Köttgen A, Levey AS, Woodward M, Eckardt KU, Hemmelgarn B, Coresh J.

Kidney Int. 2018 Jun;93(6):1442-1451. doi: 10.1016/j.kint.2018.01.009. Epub 2018 Mar 29. Erratum in: Kidney Int. 2018 Nov;94(5):1025-1026.

PMID:
29605094
17.

Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.

Kranenburg G, de Jong PA, Bartstra JW, Lagerweij SJ, Lam MG, Ossewaarde-van Norel J, Risseeuw S, van Leeuwen R, Imhof SM, Verhaar HJ, de Vries JJ, Slart RHJA, Luurtsema G, den Harder AM, Visseren FLJ, Mali WP, Spiering W.

J Am Coll Cardiol. 2018 Mar 13;71(10):1117-1126. doi: 10.1016/j.jacc.2017.12.062.

18.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.

Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC.

Diabetes Care. 2018 Jun;41(6):1244-1250. doi: 10.2337/dc17-0968. Epub 2018 Feb 22.

PMID:
29472432
19.

Arterial stiffening and thickening in patients with pseudoxanthoma elasticum.

Kranenburg G, Visseren FLJ, de Borst GJ, de Jong PA, Spiering W; SMART studygroup.

Atherosclerosis. 2018 Mar;270:160-165. doi: 10.1016/j.atherosclerosis.2018.02.006. Epub 2018 Feb 9.

PMID:
29432933
20.

Random measurement error: Why worry? An example of cardiovascular risk factors.

Brakenhoff TB, van Smeden M, Visseren FLJ, Groenwold RHH.

PLoS One. 2018 Feb 9;13(2):e0192298. doi: 10.1371/journal.pone.0192298. eCollection 2018.

21.

Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.

Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ.

Int J Cardiol. 2018 Feb 15;253:148-154. doi: 10.1016/j.ijcard.2017.10.080.

PMID:
29306457
22.

Identifying treatment response to antihypertensives in patients with obesity-related hypertension.

Schrover IM, Dorresteijn JAN, Smits JE, Danser AHJ, Visseren FLJ, Spiering W.

Clin Hypertens. 2017 Oct 24;23:20. doi: 10.1186/s40885-017-0077-x. eCollection 2017.

23.

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.

de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J.

Cardiovasc Diabetol. 2017 Oct 16;16(1):134. doi: 10.1186/s12933-017-0617-4. Review.

24.

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ.

J Lipid Res. 2017 Nov;58(11):2180-2187. doi: 10.1194/jlr.M076901. Epub 2017 Sep 19.

25.

Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.

de Beus E, van der Sande NGC, Bots ML, Spiering W, Voskuil M, Visseren FLJ, Blankestijn PJ.

BMJ Open. 2017 Sep 6;7(9):e016692. doi: 10.1136/bmjopen-2017-016692.

26.

Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes.

Engelen SE, van der Graaf Y, Stam-Slob MC, Grobbee DE, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FLJ, Westerink J; SMART study group.

Int J Cardiol. 2017 Dec 1;248:301-307. doi: 10.1016/j.ijcard.2017.07.081. Epub 2017 Jul 23.

PMID:
28802735
27.

Physical Activity and Characteristics of the Carotid Artery Wall in High-Risk Patients-The SMART (Second Manifestations of Arterial Disease) Study.

Boss HM, van der Graaf Y, Visseren FLJ, Van den Berg-Vos RM, Bots ML, de Borst GJ, Cramer MJ, Kappelle LJ, Geerlings MI; SMART Study Group.

J Am Heart Assoc. 2017 Jul 23;6(7). pii: e005143. doi: 10.1161/JAHA.116.005143.

28.

Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis.

Berkelmans GFN, van der Graaf Y, Dorresteijn JAN, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, Visseren FLJ; SMART study group.

Int J Cardiol. 2018 Jan 15;251:96-102. doi: 10.1016/j.ijcard.2017.07.026. Epub 2017 Jul 14.

29.

Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.

Matsushita K, Ballew SH, Coresh J, Arima H, Ärnlöv J, Cirillo M, Ebert N, Hiramoto JS, Kimm H, Shlipak MG, Visseren FLJ, Gansevoort RT, Kovesdy CP, Shalev V, Woodward M, Kronenberg F; Chronic Kidney Disease Prognosis Consortium.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):718-728. doi: 10.1016/S2213-8587(17)30183-3. Epub 2017 Jul 14.

30.

Trends in comorbidity in patients hospitalised for cardiovascular disease.

Buddeke J, Bots ML, van Dis I, Liem A, Visseren FLJ, Vaartjes I.

Int J Cardiol. 2017 Dec 1;248:382-388. doi: 10.1016/j.ijcard.2017.06.106. Epub 2017 Jul 10.

31.

Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease.

Kranenburg G, Spiering W, de Jong PA, Kappelle LJ, de Borst GJ, Cramer MJ, Visseren FLJ, Aboyans V, Westerink J; SMART study group.

Int J Cardiol. 2017 Oct 1;244:271-276. doi: 10.1016/j.ijcard.2017.06.044. Epub 2017 Jun 13.

PMID:
28641891
32.

Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event.

van den Berg MJ, Westerink J, van der Graaf Y, Kappelle LJ, de Borst GJ, Cramer MM, Visseren FLJ; SMART study group.

Am J Cardiol. 2017 Jul 15;120(2):167-173. doi: 10.1016/j.amjcard.2017.04.002. Epub 2017 Apr 27.

PMID:
28532782
33.

Relation between Kidney Length and Cardiovascular and Renal Risk in High-Risk Patients.

van der Sande NGC, Visseren FLJ, van der Graaf Y, Nathoe HM, de Borst GJ, Leiner T, Blankestijn PJ; SMART Study Group.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):921-928. doi: 10.2215/CJN.08990816. Epub 2017 May 9.

34.

Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.

Koopal C, Marais AD, Westerink J, Visseren FL.

J Clin Lipidol. 2017 Jan - Feb;11(1):12-23.e1. doi: 10.1016/j.jacl.2016.10.001. Epub 2016 Oct 13. Review.

PMID:
28391878
35.

Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension.

Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, Voskuil M, Spiering W.

Hypertension. 2017 May;69(5):927-932. doi: 10.1161/HYPERTENSIONAHA.116.08793. Epub 2017 Apr 3.

PMID:
28373591
36.

Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.

van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; REACH Registry investigators.

Eur Heart J. 2017 Nov 14;38(43):3211-3218. doi: 10.1093/eurheartj/ehx102.

PMID:
28369481
37.

Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population".

Kaasenbrood L, van der Graaf Y, Visseren FL.

Circulation. 2017 Mar 28;135(13):e820-e821. doi: 10.1161/CIRCULATIONAHA.117.027317. No abstract available.

PMID:
28348097
38.

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ.

N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17.

39.

Relation of Epicardial Adipose Tissue Radiodensity to Coronary Artery Calcium on Cardiac Computed Tomography in Patients at High Risk for Cardiovascular Disease.

Franssens BT, Nathoe HM, Visseren FL, van der Graaf Y, Leiner T; SMART Study Group.

Am J Cardiol. 2017 May 1;119(9):1359-1365. doi: 10.1016/j.amjcard.2017.01.031. Epub 2017 Feb 11.

PMID:
28279438
40.

Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.

Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL.

J Am Heart Assoc. 2017 Feb 18;6(2). pii: e004648. doi: 10.1161/JAHA.116.004648.

41.

Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature.

Kauw F, Kranenburg G, Kappelle LJ, Hendrikse J, Koek HL, Visseren FLJ, Mali WPT, de Jong PA, Spiering W.

J Neurol Sci. 2017 Feb 15;373:167-172. doi: 10.1016/j.jns.2016.12.053. Epub 2016 Dec 28. Review.

PMID:
28131180
42.

Relation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease.

Franssens BT, Hoogduin H, Leiner T, van der Graaf Y, Visseren FLJ.

J Magn Reson Imaging. 2017 Aug;46(2):497-504. doi: 10.1002/jmri.25594. Epub 2017 Jan 27.

PMID:
28130811
43.

Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.

Koopal C, Marais AD, Visseren FL.

Curr Opin Endocrinol Diabetes Obes. 2017 Apr;24(2):133-139. doi: 10.1097/MED.0000000000000316. Review.

PMID:
28098593
44.

Prevalence and severity of arterial calcifications in pseudoxanthoma elasticum (PXE) compared to hospital controls. Novel insights into the vascular phenotype of PXE.

Kranenburg G, de Jong PA, Mali WP, Attrach M, Visseren FL, Spiering W.

Atherosclerosis. 2017 Jan;256:7-14. doi: 10.1016/j.atherosclerosis.2016.11.012. Epub 2016 Nov 13.

PMID:
27940376
45.

The Effects of Secondary Cardiovascular Prevention on Cancer Risk in Patients With Manifest Vascular Disease.

van Kruijsdijk RC, van der Graaf Y, Algra A, de Borst GJ, Cramer MJ, Siersema PD, Peeters PH, Visseren FL; SMART study group.

J Am Coll Cardiol. 2016 Dec 13;68(23):2588-2589. doi: 10.1016/j.jacc.2016.09.950. No abstract available.

46.

Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes.

van Munster SN, van der Graaf Y, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Obes Metab. 2017 Mar;19(3):320-328. doi: 10.1111/dom.12820. Epub 2016 Dec 28.

PMID:
27807924
47.

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.

Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL.

Circulation. 2016 Nov 8;134(19):1419-1429. Epub 2016 Sep 28.

48.

Tendon xanthomas: Not always familial hypercholesterolemia.

Koopal C, Visseren FL, Marais AD, Westerink J, Spiering W.

J Clin Lipidol. 2016 Sep-Oct;10(5):1262-5. doi: 10.1016/j.jacl.2016.05.005. Epub 2016 May 14.

PMID:
27678445
49.

Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430.

Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2016 Oct;39(10):e190-1. doi: 10.2337/dci16-0023. No abstract available.

PMID:
27660133
50.

Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.

van der Leeuw J, Visseren FL, Woodward M, van der Graaf Y, Grobbee DE, Harrap S, Heller S, Mancia G, Marre M, Poulter N, Zoungas S, Chalmers J.

Diabetologia. 2016 Dec;59(12):2603-2612. Epub 2016 Sep 1.

Supplemental Content

Loading ...
Support Center